Actively Recruiting
Evaluating Lactobacillus Crispatus CRP21 Probiotic to Reduce Recurrence of Bacterial Vaginosis in Women
Led by Liaquat University of Medical & Health Sciences · Updated on 2026-09-02
132
Participants Needed
11
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying recurrent bacterial vaginosis, a common condition in women of reproductive age caused by an imbalance in vaginal bacteria. This trial evaluates whether a probiotic supplement containing Lactobacillus crispatus CRP21 can reduce the recurrence of bacterial vaginosis compared to a placebo. The study is randomized, double-blind, and placebo-controlled, focusing on women diagnosed with recurrent bacterial vaginosis who have recently completed antibiotic treatment. Participants will be randomly assigned to receive either the probiotic supplement or a placebo capsule daily for 12 weeks following standard antibiotic treatment. The probiotic aims to restore healthy vaginal bacteria, particularly Lactobacillus crispatus, which helps maintain vaginal balance. After the treatment period, participants will be followed for another 12 weeks to monitor for any recurrence of bacterial vaginosis. During the 24-week study, participants will undergo evaluations including vaginal pH measurement, symptom assessments for burning and itching, and monitoring for other genitourinary infections. Researchers will track treatment adherence, safety, and adverse events. The main goal is to see if the probiotic reduces episodes of recurrent bacterial vaginosis compared to placebo over the entire study period.
CONDITIONS
Brief Title
Evaluation of the Ability of Lactobacillus Crispatus CRP21 to Reduce the Incidence of Recurrent Bacterial Vaginosis
Research Team
D
Davide Sisti, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here